natgillin/translations-raw huggingface dataset:
The active substances in Evra are two hormones, ethinyl estradiol (an oestrogen) and norelgestromin (a progestogen).
Zdravilni učinkovini v zdravilu Evra sta dva hormona, etinilestradiol (estrogen) in norelgestromin (progesteron).
The active substances in Komboglyze, saxagliptin and metformin, each have a different mode of action to help reduce blood glucose levels and control type 2 diabetes.
Zdravilni učinkovini v zdravilu Komboglyze, saksagliptin in metformin, imata različen način delovanja, s katerim vplivata na zniževanje ravni glukoze v krvi in urejanje sladkorne bolezni tipa 2.
The active substances in Pergoveris are copies of the natural hormones FSH and LH.
Zdravilni učinkovini v zdravilu Pergoveris sta kopiji naravnih hormonov FSH in LH.
The active substances in Pergoveris are produced using a method called ‘recombinant DNA technology’: they are made by cells that have received genes (DNA) that make them able to produce follitropin alfa and lutropin alfa.
Zdravilni učinkovini zdravila Pergoveris se proizvajata po metodi, imenovani „tehnologija rekombinantne DNK“, pri kateri celice prejmejo gene (DNK), ki jim omogočajo tvorjenje folitropina alfa in lutropina alfa.
The active substances in Pergoveris, follitropin alfa and lutropin alfa, are copies of the natural hormones FSH and LH.
Zdravilni učinkovini zdravila Pergoveris, folitropin alfa in lutropin alfa, sta kopiji naravnih hormonov FSH in LH.
The active substances in Raplixa are human plasma derived fibrinogen and human thrombin.
Zdravilni učinkovini v zdravilu Raplixa sta fibrinogen iz humane plazme in humani trombin.
The active substances in Raplixa, human fibrinogen and human thrombin, are natural proteins in the blood and are obtained from blood donors.
Zdravilni učinkovini v zdravilu Raplixa, humani fibrinogen in humani trombin, sta naravni beljakovini v krvi in se pridobivata iz darovane krvi.
The active substances in RotaTeq are 5 human-bovine reassortant rotavirus strains: G1 2.2 x 106 Infectious Units
Zdravilne učinkovine cepiva RotaTeq so 5 sevov reasortiranih humano-bovinih rotavirusov: G1 2,2 x 106 infektivnih enot
The active substances in this medicine work together by blocking two different proteins that the virus needs to grow and reproduce itself, allowing the infection to be permanently eliminated from the body.
Zdravilni učinkovini v zdravilu delujeta skupaj tako, da zavirata dve različni beljakovini, ki ju virus potrebuje za svojo rast in razmnoževanje, kar omogoča, da se okužba trajno odstrani iz telesa.
The active substances in Vectra 3D act as ‘ectoparasiticides’.
Zdravilne učinkovine v zdravilo Vectra 3D so „ektoparazitiki“.
The active substances in Vectra Felis act as ectoparasiticides.
Zdravilni učinkovini v zdravilu Vectra Felis delujeta kot ektoparazitika.
The active substances in Xultophy are insulin degludec and liraglutide.
Zdravilni učinkovini v zdravilu Xultophy sta insulin degludek in liragitud.
The active substances is memantine hydrochloride.
Zdravilna učinkovina je memantinijev klorid.
The active substances of Amlodipine/Valsartan Mylan are amlodipine (as amlodipine besilate) and valsartan.
Zdravilni učinkovini v zdravilu Amlodipin/valsartan Mylan sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
The active substances of Copalia are amlodipine (as amlodipine besylate) and valsartan.
Zdravilni učinkovini v zdravilu Copalia sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
The active substances of Copalia HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Zdravilne učinkovine v zdravilu Copalia HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
The active substances of Corbilta are levodopa, carbidopa and entacapone.
Zdravilne učinkovine zdravila Corbilta so levodopa, karbidopa in entakapon.
The active substances of Dafiro are amlodipine (as amlodipine besylate) and valsartan.
Zdravilni učinkovini v zdravilu Dafiro sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
The active substances of Dafiro HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Zdravilne učinkovine v zdravilu Dafiro HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
The active substances of Eucreas, vildagliptin and metformin, belong to a group of medicines called “oral antidiabetics”.
Zdravilni učinkovini v zdravilu Eucreas, vildagliptin in metformin, sodita v skupino zdravil, ki se imenujejo “peroralni antidiabetiki”.
The active substances of Exforge are amlodipine (as amlodipine besylate) and valsartan.
Zdravilni učinkovini v zdravilu Exforge sta amlodipin (v obliki amlodipinijevega besilata) in valsartan.
The active substances of Levodopa/Carbidopa/Entacapone Orion are levodopa, carbidopa and entacapone.
Zdravilne učinkovine zdravila Levodopa/Carbidopa/Entacapone Orion so levodopa, karbidopa in entakapon.
The active substances of Numient are levodopa and carbidopa
Zdravilni učinkovini v zdravilu Numient sta levodopa in karbidopa.
The active substances of Stalevo are levodopa, carbidopa and entacapone.
Zdravilne učinkovine zdravila Stalevo so levodopa, karbidopa in entakapon.
the active substances or any of the other ingredients of this medicine (listed in section 6). neomycin.
zdravilne učinkovine ali katero koli sestavino tega cepiva (navedeno v poglavju 6). neomicin.
The active substances per dose (0.5 mL):
Zdravilne učinkovine na odmerek (0,5 ml):
The active substances,
zdravilno učinkovino
the active substances, or any of the ingredients of this medicine (listed in section 6). neomycin.
zdravilne učinkovine ali katero koli sestavino tega cepiva (navedeno v poglavju 6). neomicin
the active substances, or any of the other ingredients of this medicine (listed in section 6). neomycin.
zdravilne učinkovine ali katero koli sestavino tega cepiva (navedeno v poglavju 6). neomicin
The activities of interferon beta-1b are species-restricted and therefore, the most pertinent pharmacological information on interferon beta-1b is derived from studies of human cells in culture or in human in vivo studies.
Delovanje interferona beta-1b je omejeno na vrsto, zato najbolj ustrezni podatki o farmakologiji interferona beta- 1b izhajajo iz študij humanih celic v kulturah ali in vivo študij pri ljudeh.
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result.
Uporabljen mora biti postopek z najnižjo dozo sevanja, ki omogoča iskani diagnostični rezultat.
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended result.
Uporabljena radioaktivnost mora biti najnižja možna ob upoštevanju dejstva, da je treba doseči nameravani rezultat zdravljenja.
The activity of IntronA is expressed in terms of IU, with 1 mg of recombinant interferon alfa-2b protein corresponding to 2.6 x l08 IU.
Aktivnost zdravila IntronA izražamo v i.e., pri čemer 1 mg rekombinantne beljakovine interferona alfa-2b ustreza 2,6 x 108 i.e.
The activity of paritaprevir in genotype 1a was not significantly affected (less than or equal to 3-fold) by single substitutions V36A/M, V55I, Y56H, Q80K or E357K.
Posamične substitucije V36A/M, V55I, Y56H, Q80K ali E357K niso bistveno vplivale na aktivnost paritaprevirja pri genotipu 1a (3-krat ali manj).
The activity of Viraferon is expressed in terms of IU, with 1 mg of recombinant interferon alfa-2b protein corresponding to 2.6 x l08 IU.
Aktivnost zdravila Viraferon izražamo v i.e., pri čemer 1 mg rekombinantne beljakovine interferona alfa- 2b ustreza 2,6 x 108 i.e.
The activity per vial ranges from 1900 MBq to 28500 MBq at the date and time of calibration.
Aktivnost na vialo ob času kalibracije je v razponu med 1900 MBq in 28500 MBq.
The activity per vial ranges from 300 MBq to 3000 MBq at the date and time of calibration.
Aktivnost na vialo na dan in ob času kalibracije je v razponu med 300 MBq in 3.000 MBq.
The activity per vial ranges from 800 MBq to 12000 MBq at the date and time of calibration.
Aktivnost na vialo ob času kalibracije je v razponu med 800 MBq in 12000 MBq.
The actual amount of 13C in the breath will depend on the type of food that you have eaten.
Dejanska količina 13C je odvisna od vrste hrane, ki ste jo zaužili.
The actual amount of carbon-13 in the breath will depend on the kind of food that you have eaten.
Dejanska količina ogljika-13 v izdihanem zraku bo odvisna od hrane, ki ste jo zaužili.
The ACUITY Trial (Patients with unstable angina/non-ST segment elevated myocardial infarction (UA/NSTEMI))
Študija ACUITY (Bolniki z nestabilno angino/ miokardnim infarktom brez zvišanja intervala ST (UA/NSTEMI)
The acute symptoms and signs in these cases of overdose included agitation, confusional state, coma, bradycardia, ventricular tachycardia, Cheyne-Stokes respiration, discolourations of skin, tongue and conjunctiva, and chromaturia.
Akutni simptomi in znaki teh primerov prevelikega odmerjanja zajemajo nemir, zmedenost, komo, bradikardijo, ventrikularno tahikardijo, obliko dihanja Cheyne-Stokes, obarvanje kože, jezika, očesne veznice in kromaturija.
The adapter will snap over the vial cap.
Adapter se bo zaskočil čez zaporko viale.
The addition of 25 mg alogliptin once daily to glyburide therapy (mean dose = 12.2 mg) resulted in statistically significant improvements from baseline in HbA1c at Week 26 when compared to the addition of placebo (Table 3).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z gliburidom (povprečni odmerek = 12,2 mg) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c v primerjavi z dodatkom placeba (tabela 3).
The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z insulinom (povprečni odmerek = 56,5 i.e., z metforminom ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 3).
The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and FPG at Week 26 when compared to the addition of placebo (Table 5).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z insulinom (povprečni odmerek = 56,5 i.e., z metforminom ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 5).
The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3).
Pri dodatku alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z metforminijevim kloridom (povprečni odmerek = 1.847 mg) so bila v 26. tednu dosežena statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 3).
The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 5).
Pri dodatku alogliptina v odmerku 25 mg enkrat na dan k zdravljenju z metforminijevim kloridom (povprečni odmerek = 1.847 mg) so bila v 26. tednu dosežena statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 5).
The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s pioglitazonom (povprečni odmerek = 35,0 mg, v kombinaciji z metforminom ali s sulfonilsečnino ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 3).
The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 5).
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s pioglitazonom (povprečni odmerek = 35,0 mg, v kombinaciji z metforminom ali s sulfonilsečnino ali brez) je v 26. tednu povzročil statistično pomembna izboljšanja glede na izhodiščne vrednosti HbA1c in vrednosti glukoze v plazmi na tešče v primerjavi z dodatkom placeba (tabela 5).
The addition of amlodipine 10 mg and 5 mg produced an additional reduction in systolic/diastolic blood pressure of 6.0/4.8 mmHg and 3.9/2.9 mmHg, respectively, compared to patients who remained on valsartan 160 mg only.
V primerjavi z bolniki, ki so ostali samo na 160 mg valsartana, je dodatek 10 mg amlodipina dodatno znižal sistolični krvni tlak za 6,0 mm Hg in diastoličnega za 4,8 mm Hg, 5 mg amlodipina pa sistolični krvni tlak za 3,9mm Hg in diastoličnega za 2,9 mm Hg.
The addition of bazedoxifene in DUAVIVE reduces the risk of endometrial hyperplasia, which may be a precursor of endometrial carcinoma.
Dodatek bazedoksifena v zdravilu DUAVIVE zmanjša tveganje za hiperplazijo endometrija, ki je lahko prekurzor karcinoma endometrija.
The addition of bevacizumab to fluoropyrimidine-based chemotherapy resulted in a statistically significant prolongation of survival in patients with mCRC who have progressed on a first-line bevacizumab-containing regimen (ITT = 819) (see Table 9).
Dodatek bevacizumaba kemoterapiji na osnovi fluoropirimidina je statistično značilno podaljšal preživetje pri bolnikih z metastatskim rakom debelega črevesa in danke, pri katerih je po prvi liniji zdravljenja, ki je vključevalo bevacizumab, bolezen napredovala (ITT = 819) (glejte preglednico 9).
The addition of boceprevir to peginterferon alfa–2b and ribavirin resulted in higher incidences of neutropenia and Grade 3-4 neutropenia compared with peginterferon alfa–2b and ribavirin alone (see section 4.8).
Dodatek boceprevirja peginterferonu alfa-2b in ribavirinu je povzročil večjo pojavnost nevtropenije in nevtropenijo stopnje 3-4 v primerjavi z zdravljenjem samo s peginterferonom alfa-2b in ribavirinom (glejte poglavje 4.8)
The addition of concomitant TMZ to RT, followed by TMZ monotherapy in the treatment of patients with newly diagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).
Dodatna sočasna uporaba TMZ ob RT, ki ji sledi monoterapija s TMZ, je pri bolnikih z novo diagnosticiranim multiformnim glioblastomom pokazala statistično pomembno izboljšanje skupnega preživetja (SP) v primerjavi s samo RT (Slika 1).
The addition of erlotinib to bevacizumab did not result in an improvement in OS (HR = 1.764; p=0.1789), duration of objective response (6.7 vs 9.1 months) or time to symptom progression (HR = 1.172; p=0.5076).
Dodatek erlotiniba bevacizumabu ni prispeval k izboljšanju celokupnega preživetja (HR = 1,764; p = 0,1789), trajanja objektivnega odgovora na zdravljenje (6,7 v primerjavi z 9,1 meseca) ali časa do napredovanja simptomov (HR = 1,172; p = 0,5076).
The addition of panitumumab to radiation, chemotherapy or other targeted therapeutic agents, in animal studies resulted in an increase in anti- tumour effects compared to radiation, chemotherapy or targeted therapeutic agents alone.
Dodatek panitumumaba obsevanju, kemoterapiji ali drugim ciljanim terapevtskim sredstvom je v študijah na živalih povečal protitumorske učinke v primerjavi z uporabo obsevanja, kemoterapije ali ciljanih terapevtskih sredstev samih.
The addition of sodium chloride 9 mg/ml (0.9%) solution for injection to the lyophilised powder followed by vigorous shaking results in the production of the microbubbles of sulphur hexafluoride.
Dodatek 9 mg/ml (0,9%) raztopine natrijevega klorida za injiciranje k liofiliziranemu prašku ob močnem stresanju ustvari mikromehurčke žveplovega heksafluorida.
The addition of the entire contents of the solvent vial to the contents of the docetaxel 80 mg concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale z 80 mg Docetaksel koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of the entire contents of the solvent vial to the contents of the docetaxel 80 mg concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale zdravila Docetaxel Teva Pharma 80 mg koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of the entire contents of the solvent vial to the contents of the Docetaxel concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale Docetaksel koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of the entire contents of the solvent vial to the contents of the Docetaxel Teva 80 mg concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale zdravila Docetaksel Teva 80 mg/2,88 ml koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of the entire contents of the solvent vial to the contents of the Docetaxel Teva Pharma 20mg vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale zdravila Docetaxel Teva Pharma 20 mg koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of the entire contents of the solvent vial to the contents of the Docetaxel Teva Pharma 80 mg concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Dodatek celotne vsebine viale z vehiklom vsebini viale z 80 mg zdravila Docetaxel Teva Pharma koncentrata za raztopino za infundiranje zagotavlja koncentracijo 10 mg/ml docetaksela v osnovni raztopini.
The addition of Victrelis to peginterferon alfa–2b and ribavirin was associated to higher incidences of increase in uric acid, triglycerides and cholesterol total compared to peginterferon alfa–2b and ribavirin only.
Dodatek zdravila Victrelis k peginterferonu alfa-2b in ribavirinu je bil povezan z večjo pojavnostjo povečanih koncentracij sečne kisline, trigliceridov in celokupnega holesterola, v primerjavi z zdravljenjem s samo peginterferonom alfa-2b in ribavirinom.
The addition of water for injections to the powder for concentrate results in a total volume of 3.08 mL for a final BLINCYTO concentration of 12.5 mcg/mL.
Z dodatkom vode za injekcije prašku za koncentrat nastane celotna količina 3,08 ml za končno koncentracijo zdravila BLINCYTO 12,5 mcg/ml.
The addition or withdrawal of these medicinal products or adjusting of the dose of these medicinal products during rufinamide therapy may require an adjustment in dosage of rufinamide.
Če med zdravljenjem z rufinamidom katero od teh zdravil dodamo ali ukinemo ali prilagodimo njegov odmerek, bo mogoče treba prilagoditi odmerjanje rufinamida.
the additional
dodatnim
The additional adult studies of Pegasys in combination with ribavirin confirmed the effectiveness of Pegasys, including in patients with HIV and those who did not respond to previous treatment.
Dodatne študije so potrdile učinkovitost zdravila Pegasys, med drugim tudi pri bolnikih z virusom HIV in bolnikih, ki se niso odzivali na predhodna zdravljenja.
The additional adverse reactions in Table 2 have been reported from postmarketing surveillance or Phase IV clinical trials:
O dodatnih neželenih reakcijah (ki jih prikazuje tabela 2) so poročali v postmarketinških nadzornih ali kliničnih preskušanjih IV. faze:
The additional adverse reactions listed by system organ class and ranked by frequency in Table 2 were reported at incidence rates greater than placebo for subjects treated with celecoxib 400 mg to 800 mg daily in long-term polyp prevention trials of duration up to 3 years (the APC and PreSAP trials;
Dodatni neželeni učinki, navedeni po organskih sistemih in razvrščeni po pogostnosti v preglednici 2, so bili opisani z incidenco večjo kot pri placebu med preiskovanci, zdravljenimi s celekoksibom od 400 do 800 mg na dan v dolgoročnih preskušanjih preprečevanja polipov, ki so trajala do 3 leta (preskušanji APC in PreSAP; glejte poglavje 5.1, Farmakodinamične lastnosti: Srčnožilna varnost – dolgoročne študije pri bolnikih s sporadičnimi adenomatoznimi polipi).
The additional course(s) of LEMTRADA were administered at 12 mg/day for 3 consecutive days (36 mg total dose) at least 12 months after the prior treatment course.
Dodatno zdravljenje z zdravilom LEMTRADA v odmerku 12 mg/dan je trajalo 3 zaporedne dni (skupni odmerek 36 mg) in sicer vsaj 12 mesecev po predhodnem zdravljenju.
The additional data showed that previously untreated patients given Yervoy 3 mg per kg bodyweight survived for an average of 13.5 months.
Dodatni podatki so pokazali, da so predhodno nezdravljeni bolniki, ki so prejemali zdravilo Yervoy v odmerku 3 mg na kg telesne mase, v povprečju preživeli 13,5 meseca.
The additional studies confirmed Advate’s effectiveness, including in children under six years of age.
Dodatne študije so potrdile učinkovitost zdravila Advate, vključno pri otrocih, mlajših od šest let.
The additional studies showed that booster vaccinations with Infanrix hexa were as effective as separate vaccines containing the same active substances one month after the booster vaccination.
Dodatne študije so pokazale, da so bila obnovitvena cepljenja s cepivom Infanrix hexa en mesec po obnovitvenem cepljenju enako učinkovita kot ločena cepiva, ki so vsebovala enake zdravilne učinkovine.
The additional studies showed that protection against hepatitis B from PROCOMVAX was adequate in infants who had and who had not received hepatitis B vaccination in the past.
Dodatne študije so pokazale, da je zaščita, ki jo proti hepatitisu B nudi zdravilo PROCOMVAX, ustrezna tako pri dojenčkih, ki so bili predhodno cepljeni proti hepatitisu B, kot tudi pri tistih, ki tega celjenja predhodno niso prejeli.
The additional studies showed that protection against Japanese encephalitis virus lasted for at least two to three years in most people vaccinated with Ixiaro.
Dodatne študije so pokazale, da je zaščita proti virusu japonskega encefalitisa pri večini ljudi, cepljenih s cepivom Ixiaro, trajala vsaj dve do tri leta.
The additional studies showed that Synflorix led to an increase in antibody production following booster vaccinations.
Dodatne študije so pokazale, da se je s cepivom Synflorix po obnovitvenih cepljenjih povečala tvorba protiteles.
The additional studies showed that the prolonged-release tablets were as effective as the immediate- release tablets in HIV-infected patients.
Dodatne študije so pokazale, da so pri bolnikih, okuženih z virusom HIV, tablete s podaljšanim sproščanjem enako učinkovite kot tablete s takojšnjim sproščanjem.